CA2686584A1 - Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler - Google Patents

Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler Download PDF

Info

Publication number
CA2686584A1
CA2686584A1 CA2686584A CA2686584A CA2686584A1 CA 2686584 A1 CA2686584 A1 CA 2686584A1 CA 2686584 A CA2686584 A CA 2686584A CA 2686584 A CA2686584 A CA 2686584A CA 2686584 A1 CA2686584 A1 CA 2686584A1
Authority
CA
Canada
Prior art keywords
plasmodium
protease
compound
vivo
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA2686584A
Other languages
English (en)
Inventor
Jean-Christophe Barale
Anthony Bouillon
David Giganti
Olivier Louis Gabriel Gorgette
Veronique Stoven
Michael Nilges
Odile Puijalon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to CA2686584A priority Critical patent/CA2686584A1/fr
Publication of CA2686584A1 publication Critical patent/CA2686584A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2686584A 2009-11-27 2009-11-27 Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler Withdrawn CA2686584A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2686584A CA2686584A1 (fr) 2009-11-27 2009-11-27 Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2686584A CA2686584A1 (fr) 2009-11-27 2009-11-27 Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler

Publications (1)

Publication Number Publication Date
CA2686584A1 true CA2686584A1 (fr) 2011-05-27

Family

ID=43939879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2686584A Withdrawn CA2686584A1 (fr) 2009-11-27 2009-11-27 Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler

Country Status (1)

Country Link
CA (1) CA2686584A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046030A3 (fr) * 2010-10-07 2012-08-09 Riotech Pharmaceuticals Ltd Inhibiteurs de phosphodiestérase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046030A3 (fr) * 2010-10-07 2012-08-09 Riotech Pharmaceuticals Ltd Inhibiteurs de phosphodiestérase

Similar Documents

Publication Publication Date Title
Yeoh et al. Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes
Mbengue et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria
US11964944B2 (en) Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
Rosenthal et al. Plasmodium falciparum artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response
Skinner-Adams et al. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds
Wang et al. A protein palmitoylation cascade regulates microtubule cytoskeleton integrity in Plasmodium
Le Chat et al. The role of metacaspase 1 in Plasmodium berghei development and apoptosis
da Fonseca Pires et al. Identification of virulence factors in Leishmania infantum strains by a proteomic approach
Chung et al. Post-translational modifications in Plasmodium: more than you think!
Teuscher et al. The M18 aspartyl aminopeptidase of the human malaria parasite Plasmodium falciparum
Griffith et al. Dense granule biogenesis, secretion, and function in Toxoplasma gondii
Krishnan et al. Torin 2 derivative, NCATS-SM3710, has potent multistage antimalarial activity through inhibition of P. falciparum phosphatidylinositol 4-kinase (Pf PI4KIIIβ)
Kosec et al. Cysteine proteinases of Trypanosoma cruzi: from digestive enzymes to programmed cell death
da Cruz et al. FRET peptides reveal differential proteolytic activation in intraerythrocytic stages of the malaria parasites Plasmodium berghei and Plasmodium yoelii
Groat‐Carmona et al. AP lasmodium α/β‐hydrolase modulates the development of invasive stages
Vo et al. The protozoan parasite Toxoplasma gondii encodes a gamut of phosphodiesterases during its lytic cycle in human cells
CA2686584A1 (fr) Inhibiteurs des proteases de plasmodium et methodes de criblage in silico permettant de les deceler
Angrisano et al. Male-specific protein disulphide isomerase function is essential for Plasmodium transmission and a vulnerable target for intervention
Jaijyan et al. A novel FIKK kinase regulates the development of mosquito and liver stages of the malaria
EP2646568B1 (fr) Procédés de criblage pour l'identification d'inhibiteurs de protéases de plasmodium
Liang et al. Characteristics analyses of Eimeria tenella 14-3-3 protein and verification of its interaction with calcium-dependent protein kinase 4
Polonais et al. Toxoplasma gondii aspartic protease 1 is not essential in tachyzoites
Lu et al. Localization and enzyme kinetics of aminopeptidase N3 from Toxoplasma gondii
Wang et al. Identification and characterization of the lamprey cathepsin genes
Alam et al. Functional attribution of LdISP, an endogenous serine protease inhibitor from Leishmania donovani in promoting infection

Legal Events

Date Code Title Description
AZWI Withdrawn application